Cevostamab after CAR-T Cell Therapy

Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma

What's the purpose of the trial?

Aiming to assess the impact of cevostamab consolidation post-BCMA CAR T cell therapy on rate of MRD-negative complete remission (CR) at 12 months.

Trial status

Accepting patients

Phase
Phase 2
Enrollment
30
Last Updated
3 weeks ago
Patient Screener

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Cevostamab is a bispecific T-cell engager antibody that targets both FCRH5 found on cancer cells and CD3 antigen found on T lymphocytes.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Cevostamab

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.